<span>Navigating the genetic complexity of autism spectrum disorder (ASD) with insights from Labcorp's Reveal® SNP Microarray Pediatric Test</span>
May 3, 2024

Navigating the genetic complexity of autism spectrum disorder (ASD) with insights from Labcorp's Reveal® SNP Microarray Pediatric Test

Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder typically characterized by deficits in social behaviors and communication skills emerging within the first three years of life. Given ASD’s spectrum nature and the absence of clear biomarkers or diagnostic measures, it’s important to understand ASD’s genetic origins.
Read more »
April 25, 2024

Labcorp Announces 2024 First Quarter Results

Updates Full-Year Guidance Results from Continuing Operations for first quarter 2024 versus last year: Revenue: $3.18 billion versus $3.04 billion or up 4.6% | Base Business grew 6.7% Diluted EPS: $2.69 versus $2.34 Adjusted EPS: $3.68 versus $3.46 Full-Year 2024 Guidance: Raised midpoint and
Read more »
April 25, 2024

Labcorp Announces Winning Bid for Select Assets of Invitae

Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 BURLINGTON, N.C. , April 24, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and
Read more »
April 7, 2024

Enhanced Detection of ctDNA Molecular Response for Immunotherapy Treated Non-small Cell Lung Cancer Through Analyses of Cell-free and Matched White Blood Cell DNA

In this real-world study of patients with advanced NSCLC treated with immune checkpoint inhibitors, integrated analysis of ctDNA and matched white blood cells measured molecular response through longitudinal liquid biopsy and more accurately predicted radiographic response and overall survival.

Read more »